Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262. PMID:25651787.
   PubMed Web of Science ®Google Scholar
• Small W, Jr., Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, et al. Cervical cancer: A global health crisis. Cancer. 2017;123:2404–2412. doi:10.1002/cncr.30667. PMID:28464289.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.21338. PMID:26808342.
   PubMed Web of Science ®Google Scholar
• Mountzios G, Soultati A, Pectasides D, Pectasides E, Dimopoulos MA, Papadimitriou CA. Developments in the systemic treatment of metastatic cervical cancer. Cancer Treat Rev. 2013;39:430–443. doi:10.1016/j.ctrv.2012.05.009. PMID:22727690.
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15:755–772. doi:10.2337/diacare.15.6.755. PMID:1600835.
   PubMed Web of Science ®Google Scholar
• Fujimoto S. Therapeutic utility of biguanides in the treatment of NIDDM. Nihon Rinsho. 1999;57:657–662. PMID:10199150.
   PubMedGoogle Scholar
• McIntyre HD, Ma A, Bird DM, Paterson CA, Ravenscroft PJ, Cameron DP. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust N Z J Med. 1991;21:714–719. doi:10.1111/j.1445-5994.1991.tb01375.x. PMID:1759920.
   PubMedGoogle Scholar
• Lisch HJ, Sailer S, Braunsteiner H. The effect of biguanides on insulin sensitivity of maturity onset diabetics (author's transl). Wien Klin Wochenschr. 1980;92:266–269. PMID:6996339.
   PubMed Web of Science ®Google Scholar
• Wang CP, Lehman DM, Lam YF, Kuhn JG, Mahalingam D, Weitman S, Lorenzo C, Downs JR, Stuart EA, Hernandez J, et al. Metformin for reducing Racial/Ethnic difference in Prostate Cancer Incidence for Men with Type II diabetes. Cancer Prev Res (Phila). 2016;9:779–787. doi:10.1158/1940-6207.CAPR-15-0425. PMID:27026681.
   PubMed Web of Science ®Google Scholar
• Arima R, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Kangaskokko J, Laara E, Puistola U, Hinkula M. Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes. Gynecol Oncol. 2017;146:636–641. doi:10.1016/j.ygyno.2017.06.011. PMID:28645427.
   PubMed Web of Science ®Google Scholar
• Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X, Liu Y, Rui D, Nie S, Xiang H. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Oncotarget. 2017;8:16017–16026. PMID:27926481.
   PubMedGoogle Scholar
• Tseng CH. Metformin and lung cancer risk in patients with type 2 diabetes mellitus. Oncotarget. 2017;8:41132–41142. PMID:28456789.
   PubMedGoogle Scholar
• Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Tyndyk ML, Anikin IV, Semenchenko AV, Yashin AI. Central and peripheral effects of insulin/IGF-1 signaling in aging and cancer: antidiabetic drugs as geroprotectors and anticarcinogens. Ann N Y Acad Sci. 2005;1057:220–234. doi:10.1196/annals.1356.017. PMID:16399897.
   PubMed Web of Science ®Google Scholar
• Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol. 2008;233:203–210. doi:10.1016/j.taap.2008.08.013. PMID:18817800.
   PubMed Web of Science ®Google Scholar
• Appleyard MV, Murray KE, Coates PJ, Wullschleger S, Bray SE, Kernohan NM, Fleming S, Alessi DR, Thompson AM. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br J Cancer. 2012;106:1117–1122. doi:10.1038/bjc.2012.56. PMID:22361631.
   PubMed Web of Science ®Google Scholar
• Orecchioni S, Reggiani F, Talarico G, Mancuso P, Calleri A, Gregato G, Labanca V, Noonan DM, Dallaglio K, Albini A, et al. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer. 2015;136:E534–544. doi:10.1002/ijc.29193. PMID:25196138.
   PubMed Web of Science ®Google Scholar
• Kilgore J, Jackson AL, Clark LH, Guo H, Zhang L, Jones HM, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL. Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells. Am J Transl Res. 2016;8:2705–2715. PMID:27398153.
   PubMed Web of Science ®Google Scholar
• Hanly EK, Darzynkiewicz Z, Tiwari RK. Biguanides and targeted anti-cancer treatments. Genes Cancer. 2015;6:82–83. PMID:26000092.
   PubMedGoogle Scholar
• Alexandrov VA, Anisimov VN, Belous NM, Vasilyeva IA, Mazon VB. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats. Carcinogenesis. 1980;1:975–978. doi:10.1093/carcin/1.12.975. PMID:11272113.
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Aleksandrov VA, Belous NM, Vasil'eva IA, Matson VB. Inhibition of the transplacental blastomogenic effect of N-nitrosomethylurea in rats by buformin. Biull Eksp Biol Med. 1980;89:88–90. PMID:6996759.
   PubMedGoogle Scholar
• Zhu Z, Jiang W, Thompson MD, Echeverria D, McGinley JN, Thompson HJ. Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat. Cancer Prev Res (Phila). 2015;8:518–527. doi:10.1158/1940-6207.CAPR-14-0121. PMID:25804611.
   PubMed Web of Science ®Google Scholar
• Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, Bae-Jump VL. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 2012;125:458–469. doi:10.1016/j.ygyno.2012.01.009. PMID:22252099.
   PubMed Web of Science ®Google Scholar
• Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero IL. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015;212:479 e471–479 e410. doi:10.1016/j.ajog.2014.10.026.
   Web of Science ®Google Scholar
• Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, et al. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget. 2016;7:4265–4278. doi:10.18632/oncotarget.6559. PMID:26673006.
   PubMedGoogle Scholar
• Guo Z, Zhao M, Howard EW, Zhao Q, Parris AB, Ma Z, Yang X. Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway. Oncotarget. 2017;8:60342–60357. PMID:28947975.
   PubMedGoogle Scholar
• Shi P, Liu W, Tala Wang H, Li F, Zhang H, Wu Y, Kong Y, Zhou Z, Wang C, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov. 2017;3:17010. doi:10.1038/celldisc.2017.10. PMID:28480051.
   PubMed Web of Science ®Google Scholar
• Wittmann P, Haslbeck M, Bachmann W, Mehnert H. Lactic acidosis in diabetics on biguanides (author's transl). Dtsch Med Wochenschr. 1977;102:5–10. doi:10.1055/s-0028-1104832. PMID:11984.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy M, Sahouria JJ, Desai R, Caguiat J. Buformin-induced lactic acidosis–a symptom of modern healthcare malady. J Am Geriatr Soc. 2004;52:1785. doi:10.1111/j.1532-5415.2004.52479_7.x. PMID:15450070.
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Semenchenko AV, Yashin AI. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology. 2003;4:297–307. doi:10.1023/A:1026299318315. PMID:14618027.
   PubMed Web of Science ®Google Scholar
• Yano A, Kubota M, Iguchi K, Usui S, Hirano K. Buformin suppresses the expression of glyceraldehyde 3-phosphate dehydrogenase. Biol Pharm Bull. 2006;29:1006–1009. doi:10.1248/bpb.29.1006. PMID:16651735.
   PubMed Web of Science ®Google Scholar
• Parris AB, Zhao Q, Howard EW, Zhao M, Ma Z, Yang X. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice. J Exp Clin Cancer Res. 2017;36:28. doi:10.1186/s13046-017-0498-0. PMID:28193239.
   PubMed Web of Science ®Google Scholar
• Yee GP, de Souza P, Khachigian LM. Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 2013;13:205–220. doi:10.2174/1568009611313020009. PMID:23259831.
   PubMed Web of Science ®Google Scholar
• Qi X, Xu W, Xie J, Wang Y, Han S, Wei Z, Ni Y, Dong Y, Han W. Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-kappaB/HIF-1alpha signal axis. Sci Rep. 2016;6:35788. doi:10.1038/srep35788. PMID:27762347.
   PubMed Web of Science ®Google Scholar
• Liu Y, He C, Huang X. Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism. Oncotarget. 2017;8:75206–75216. PMID:29088858.
   PubMedGoogle Scholar
• Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med. 1992;152:2333–2336. doi:10.1001/archinte.1992.00400230129023. PMID:1444694.
   PubMed Web of Science ®Google Scholar
• Lea MA, Chacko J, Bolikal S, Hong JY, Chung R, Ortega A, Desbordes C. Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin. Anticancer Res. 2011;31:421–426. PMID:21378320.
   PubMed Web of Science ®Google Scholar
• Godo S, Yoshida Y, Fujita M, Kudo D, Nomura R, Shimokawa H, Kushimoto S. The dramatic recovery of a Patient with Biguanide-associated Severe Lactic Acidosis following Thiamine supplementation. Intern Med. 2017;56:455–459. doi:10.2169/internalmedicine.56.7754. PMID:28202871.
   PubMed Web of Science ®Google Scholar